EUCTR2014-002083-33-GB进行中（未招募）1 期
Does Allopurinol regress Left Ventricular Hypertrophy in Patients with Treated Essential Hypertension? - The ALLAY Trial
niversity of Dundee/NHS Tayside0 个研究点目标入组 66 人开始时间: 2014年6月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •are aged over 18 years
- •previously diagnosed with essential hypertension
- •been on stable antihypertensive therapy for at least 3 months prior to study screening
- •have screening ABPM (or home based BP monitoring if ABPM not tolerated) with daytime average systolic <135mmHg
- •have screening echocardiography based diagnosis of LVH based on ASE criteria (males >115g/m2, females >95g/m2)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 44
排除标准
- •documented intolerance to allopurinol
- •left Ventricular Ejection Fraction <45% on echocardiography screening
- •severe aortic stenosis on echocardiography screening
- •already had gout or currently on allopurinol
- •severe hepatic disease
- •renal disease; CKD class 3B or worse
- •on azathioprine, 6 mercaptopurine, or theophylline
- •malignancy (receiving active treatment) or other life threatening diseases
- •pregnant or lactating women
- •any contraindication to MRI (claustrophobia, metal implants)
- •patients who have participated in any other clinical trial of an investigational medicinal product within the previous 30 days will be excluded.
- •patients who are unable to give informed consent
- •any other considered by a study physician to be inappropriate for inclusion
研究者
相似试验
进行中（未招募）
1 期
The Altered study: Does Allopurinol regress left ventricular hypertrophy in End stage Renal DiseaseRenal failure and left ventricular hypertrophyEUCTR2013-001436-22-GBniversity of Dundee/NHS Tayside86
已完成
不适用
Does allopurinol reduce thickening of the left ventricle of the heart in patients with treated hypertension?Essential hypertensives with left ventricular hypertrophyCirculatory SystemISRCTN40476871The University of Dundee and NHS Tayside (UK)72
已完成
4 期
Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?Hypertrophy, Left VentricularHypertensionNCT02237339University of Dundee72
已完成
不适用
Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?Myocardial infarctionCirculatory SystemISRCTN57354520niversity of Dundee (UK)36
进行中（未招募）
1 期
The ALPHA Trialright ventricular hypertrophy associated with COPD or Interstitial Lung Disease and pulmonary hypertensionMedDRA version: 17.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.1 Level: PT Classification code 10022611 Term: Interstitial lung disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.1 Level: PT Classification code 10050326 Term: Right ventricular hypertrophy System Organ Class: 10007541 - Cardiac disordersEUCTR2014-002305-38-GBniversity of Dundee/ NHS Tayside72